Simone de Sales Costa Moreira Carboni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Simone de Sales Costa Moreira Carboni has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Anna Cecília Dias Maciel Carneiro
Medical Clinical Department, Institute of Health Sciences, Federal University of Triângulo Mineiro, Uberaba, MG, Brazil
2 shared publications - Virginia Oliveira Crema
Federal University of Triângulo Mineiro
2 shared publications - Arthur Ferreira Rezende
Federal University of Triângulo Mineiro
1 shared publication - Bruna Raphaela Oliveira Silva
Federal University of Triângulo Mineiro
1 shared publication - Guilherme Henrique Borges
Graduate Program in Dentistry, School of Dentistry, Universidade Federal de Uberlândia (UFU), Av. Pará, 1720, Umuarama District, Uberlândia, Minas Gerais 38405-320, Brazil
1 shared publication - Isadora Caixeta da Silveira Ferreira
Federal University of Triângulo Mineiro
1 shared publication
Latest Publications
- Open Access
- 6 February 2022
- Published by Research, Society and Development in Research, Society and Development
- Vol. 11 (3)
HA1077 inhibits cell proliferation of oral squamous cell carcinoma in vitro
Oral squamous cell carcinoma is a common malignant lesion. ROCKs proteins are associated with pathogenesis and progression of human tumours. This study aimed to evaluate the functional role of ROCKs in the regulation of cell proliferation of oral squamous cell carcinoma in vitro. BrdU incorporation assays and KI-67 immunoexpression were performed by using SCC-4 cell line from oral squamous cell carcinoma. Control and treated cells: HA-1077 (25, 50 and 100 μmol/l), 50 μmol HA-1077 and Y-27632 30 μmol/l, Y-27632 30 μmol/l were cutured for 6 h. The number of SCC-4 cells treated with: HA-1077 (25, 50 and 100 μmol/l), HA-1077 50 μmol/l and/or Y-27632 30 μmol/l was significantly lower than control cells in BrdU assay [F (5.17) = 443.818, p<0.0001] and in KI-67 assay [F = 192.595, d.f. = 5,17; p<0.0001]. The results obtained suggest that the pathways that evolve ROCKs proteins play an important functional role in the positive regulation of cell proliferation in oral squamous cell carcinoma.
- 6 February 2022
- Published by Research, Society and Development in Research, Society and Development
- Vol. 11 (3)
Open AccessHA1077 inhibits cell proliferation of oral squamous cell carcinoma in vitro
Oral squamous cell carcinoma is a common malignant lesion. ROCKs proteins are associated with pathogenesis and progression of human tumours. This study aimed to evaluate the functional role of ROCKs in the regulation of cell proliferation of oral squamous cell carcinoma in vitro. BrdU incorporation assays and KI-67 immunoexpression were performed by using SCC-4 cell line from oral squamous cell carcinoma. Control and treated cells: HA-1077 (25, 50 and 100 μmol/l), 50 μmol HA-1077 and Y-27632 30 μmol/l, Y-27632 30 μmol/l were cutured for 6 h. The number of SCC-4 cells treated with: HA-1077 (25, 50 and 100 μmol/l), HA-1077 50 μmol/l and/or Y-27632 30 μmol/l was significantly lower than control cells in BrdU assay [F (5.17) = 443.818, p<0.0001] and in KI-67 assay [F = 192.595, d.f. = 5,17; p<0.0001]. The results obtained suggest that the pathways that evolve ROCKs proteins play an important functional role in the positive regulation of cell proliferation in oral squamous cell carcinoma.
- Open Access
- 18 July 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (9)
Potential therapy with the inhibitor of TGF-β receptors LY2109761 for oral squamous cell carcinoma
One way of trying to control oral squamous cell carcinoma is to invest in new therapies focused on the molecular biology of receptors and their intracellular signaling pathways. This study aimed to evaluate the effect of LY2109761 (an inhibitor of TGF-β receptors) on cell migration in oral squamous cell carcinoma in vitro. Actin cytoskeleton of SCC-4 cells control and LY2109761 (1, 5 and 10 μM) treated on three-dimensional Matrigel were analysed by using confocal laser microscopy. Control and LY2109761 (1, 5 and 10 μM) treated cells that migrated through the membrane of three-dimensional cell migration assays were counted, significance was p<0.05. Control cells were seen with voluminous cytoplasm, cell cortex preserved and actin cytoskeleton well developed with well distributed actin filaments. Regardless of concentration, cells treated showed: rounded morphology and small size, scanty cytoplasm, cortical F-actin less clear that the control cells, and disruption of actin filaments. The migratory cells were inhibited by treatment with LY2109761 [F (3, 11) = 3742, p<0.0001], in a dose-dependent manner. These results suggest that LY2109761 exerts an inhibitory effect on the actin cytoskeleton and cell migration on SCC-4 cells, therefore, it is a promising therapeutic option for oral squamous cell carcinoma.
- 18 July 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (9)
Open AccessPotential therapy with the inhibitor of TGF-β receptors LY2109761 for oral squamous cell carcinoma
One way of trying to control oral squamous cell carcinoma is to invest in new therapies focused on the molecular biology of receptors and their intracellular signaling pathways. This study aimed to evaluate the effect of LY2109761 (an inhibitor of TGF-β receptors) on cell migration in oral squamous cell carcinoma in vitro. Actin cytoskeleton of SCC-4 cells control and LY2109761 (1, 5 and 10 μM) treated on three-dimensional Matrigel were analysed by using confocal laser microscopy. Control and LY2109761 (1, 5 and 10 μM) treated cells that migrated through the membrane of three-dimensional cell migration assays were counted, significance was p<0.05. Control cells were seen with voluminous cytoplasm, cell cortex preserved and actin cytoskeleton well developed with well distributed actin filaments. Regardless of concentration, cells treated showed: rounded morphology and small size, scanty cytoplasm, cortical F-actin less clear that the control cells, and disruption of actin filaments. The migratory cells were inhibited by treatment with LY2109761 [F (3, 11) = 3742, p<0.0001], in a dose-dependent manner. These results suggest that LY2109761 exerts an inhibitory effect on the actin cytoskeleton and cell migration on SCC-4 cells, therefore, it is a promising therapeutic option for oral squamous cell carcinoma.